This includes, among others, the upregulation of RAB10 (Figure 7E), which was recently suggested as novel therapeutic target for ovarian cancer in virtue of its activity as regulator of cell migration (118) or the downregulation of PAWR whose loss is considered a clinical biomarker for ovarian cancer cell progression (91). This evidence concerns the gene RAB10 and ovarian carcinoma.